Unicycive Therapeutics (UNCY) Stock Overview
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
UNCY Community Fair Values
Create NarrativeSee what 187 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Unicycive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.08 |
| 52 Week High | US$11.00 |
| 52 Week Low | US$3.71 |
| Beta | 1.77 |
| 1 Month Change | 10.84% |
| 3 Month Change | 17.27% |
| 1 Year Change | 46.06% |
| 3 Year Change | -40.15% |
| 5 Year Change | n/a |
| Change since IPO | -86.19% |
Recent News & Updates
UNCY: Redefining Chronic Kidney Disease Outcomes by Overcoming the Adherence Barriers of Traditional Phosphate Binder Regimens
Unicycive Therapeutics, Inc. (UNCY), a clinical-stage biotechnology firm specializing in kidney disease, is navigating a high-stakes structural breakout in 2026.
Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
I'm not an expert in this field, so I use Copilot to gather information and automate reports. If you notice any inconsistencies that I missed, please let me know so I can revise the model.Recent updates
UNCY: Redefining Chronic Kidney Disease Outcomes by Overcoming the Adherence Barriers of Traditional Phosphate Binder Regimens
Unicycive Therapeutics, Inc. (UNCY), a clinical-stage biotechnology firm specializing in kidney disease, is navigating a high-stakes structural breakout in 2026.Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization
I'm not an expert in this field, so I use Copilot to gather information and automate reports. If you notice any inconsistencies that I missed, please let me know so I can revise the model.We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Unicycive Therapeutics (NASDAQ:UNCY) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Unicycive Therapeutics (NASDAQ:UNCY) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...We Think Unicycive Therapeutics (NASDAQ:UNCY) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That Unicycive Therapeutics (NASDAQ:UNCY) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Not Very Worried About Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Unicycive...We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Unicycive Therapeutics (NASDAQ:UNCY) said treatment with UNI-494 showed a statistically significant reduction of a key biomarker of kidney injury in a preclinical study of an animal model of acute kidney injury (AKI). The company evaluated the effect of UNI-494 on ischemia-reperfusion induced acute kidney injury (IR-AKI) in rats. Unicycive said UNI-494 was given orally 1-hour before the induction of ischemia, and kidney function was monitored by measuring urinary creatinine, total urinary albumin, and β-2 microglobulin (β-2 MG). Treatment of the animals with the higher dose of UNI-494 resulted in a statistically significant reduction of β-2 MG levels in urine, the company said in a Sept. 7 press release. "We remain on track to file a regulatory submission by the end of 2022 that will allow us to initiate our Phase 1 study with UNI-494," said Unicycive CEO Shalabh Gupta. UNCY +25.35% to $0.89 premarket Sept. 7Unicycive Therapeutics GAAP EPS of -$0.24
Unicycive Therapeutics press release (NASDAQ:UNCY): Q2 GAAP EPS of -$0.24. As June 30, 2022, cash and cash equivalents totaled $10.6M.Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Unicycive Therapeutics (NASDAQ:UNCY) granted exclusive rights to Lee's Pharmaceutical (HK) to develop, market and commercialize Renazorb in Mainland China, Hong Kong, and certain other Asian markets. Unicycive said Renazorb (lanthanum dioxycarbonate) is its novel phosphate binding agent being developed to treat hyperphosphatemia (high level of phosphate) in patients with chronic kidney disease (CKD). Under the agreement, Unicycive will receive $1M upfront upon signature and and up to $1M in milestones upon product launch in China and will be eligible for royalties upon regulatory and commercial achievements. Lee's Pharmaceutical, which is a unit of Hong Kong-based Lee's Pharmaceutical Holdings (OTC:LPCUF), will be responsible for developing, registration filing and approval of Renazorb in the licensed territories and will also be solely responsible for importing the drug product from Unicycive and for the costs of selling Renazorb in the regions, according to Unicycive's July 18 press release.Shareholder Returns
| UNCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.9% | 2.4% | 1.1% |
| 1Y | 46.1% | 34.6% | 28.7% |
Return vs Industry: UNCY exceeded the US Biotechs industry which returned 34.6% over the past year.
Return vs Market: UNCY exceeded the US Market which returned 28.7% over the past year.
Price Volatility
| UNCY volatility | |
|---|---|
| UNCY Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UNCY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: UNCY's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 22 | Shalabh Gupta | unicycive.com |
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Unicycive Therapeutics, Inc. Fundamentals Summary
| UNCY fundamental statistics | |
|---|---|
| Market cap | US$215.74m |
| Earnings (TTM) | -US$39.95m |
| Revenue (TTM) | n/a |
Is UNCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNCY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$39.95m |
| Earnings | -US$39.95m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UNCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 04:47 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unicycive Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kumaraguru Raja | Brookline Capital Markets |